Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)

Published:2017-08-10 Issue:1 Volume:36 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

Xia Guanggai,Wang Hongcheng,Song Ziliang,Meng Qingcai,Huang Xiuyan,Huang Xinyu

Funder

Shanghai Committee of Science and Technology

The National Natural Science Foundation of China

The International Foundation of Translational Medicine for Abroad Scholars and Students, U.S. and China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s13046-017-0579-0.pdf

Reference53 articles.

1. Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet. 2016;388:73–85.

2. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

3. Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.

4. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.

5. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma;Drug Resistance Updates;2024-11

2. AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer;Nature Communications;2024-08-30

3. Emerging mechanisms and promising approaches in pancreatic cancer metabolism;Cell Death & Disease;2024-08-01

4. The potential of ribonucleotide reductase M2 as a novel prognostic maker and therapeutic target to inhibit medulloblastoma proliferation, migration, and invasiveness;Pediatric Discovery;2024-07-31

5. Role of Phytoconstituents in Cancer Treatment: A Review;Recent Advances in Food, Nutrition & Agriculture;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3